1. Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE. (25th November 2020) Authors: Mahaffey, K.W; Bakris, G; Blais, J; Cannon, C.P; Cherney, D; Damaraju, C.V; Gogate, J; Greene, T; Heerspink, H.J.L; Januzzi Jr, J.L; Kosiborod, M; Levin, A; Lingvay, I; Weir, M; Perkovic, V Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial. (25th November 2020) Authors: Mahaffey, K.W; Li, J; Chang, T.I; Sarraju, A; Agarwal, R; Charytan, D.M; Greene, T; Heerspink, H.J.L; Levin, A; Neal, B; Pollock, C; Yavin, Y; Jardine, M; Perkovic, V; Cannon, C.P Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial. (25th November 2020) Authors: Scholtes, R; Muskiet, M.H.A; Van Baar, M.J.B; Greasley, P.J; Karlsson, C; Hammarsterdt, A; Arya, N; Van Raalte, D.H; Heerspink, H.J.L Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗